Julia Minitti is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patent and innovation strategies practice. Julia counsels clients in the biotechnology, chemical, and pharmaceutical industries on a wide range of intellectual property issues, including patent portfolio development and management, Orange Book listing, patentability, non-infringement, and freedom to operate. She also advises clients in connection with various transactions, such as mergers and acquisitions, licenses, and venture financings.
Julia obtained her Ph.D. in organic chemistry from Brown University, where she worked on synthetic methodology for creating heterocycles and catalyzing conjugate additions. Prior to graduate school, she worked as a medicinal chemist at Albany Molecular Research.
Julia currently serves as co-chair of the Hiring Committee for the firm and the patent and innovations group.
Julia Minitti is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patent and innovation strategies practice. Julia counsels clients in the biotechnology, chemical, and pharmaceutical industries on a wide range of intellectual property issues, including patent portfolio development and management, Orange Book listing, patentability, non-infringement, and freedom to operate. She also advises clients in connection with various transactions, such as mergers and acquisitions, licenses, and venture financings.
Julia obtained her Ph.D. in organic chemistry from Brown University, where she worked on synthetic methodology for creating heterocycles and catalyzing conjugate additions. Prior to graduate school, she worked as a medicinal chemist at Albany Molecular Research.
Julia currently serves as co-chair of the Hiring Committee for the firm and the patent and innovations group.
- J.D., Santa Clara University School of Law
- Ph.D., Organic Chemistry, Brown University
- B.S., Chemistry, Union CollegeCum Laude
- State Bar of California
- U.S. Patent and Trademark Office
- J.D., Santa Clara University School of Law
- Ph.D., Organic Chemistry, Brown University
- B.S., Chemistry, Union CollegeCum Laude
- State Bar of California
- U.S. Patent and Trademark Office
Select Clients
- Aeovian Pharmaceuticals
- Edgewise Therapeutics
- Orca Biosystems
- Pharmatrophix
- Presage Biosciences
- Silverback Therapeutics
- Unity Biotechnology
- ViewPoint Therapeutics
Select Clients
- Aeovian Pharmaceuticals
- Edgewise Therapeutics
- Orca Biosystems
- Pharmatrophix
- Presage Biosciences
- Silverback Therapeutics
- Unity Biotechnology
- ViewPoint Therapeutics
Select Publications
- Co-author with W.C. Trenkle, D.A. Sweigart, and S. Son, "Highly Efficient 1,4-Additions of Electron Deficient Aryl Boronic acids with a Novel Rh (I) Catalyst," 25(15) Organometallics 3548-51, 2006
- Co-author with M.D. Faust Jr. and W.C. Trenkle, "Cytosine Analogues from Substituted Acetonitriles via Thorpe Condensation," 5(18) Organic Letters 3333-5, 2003
- Co-author with J.C. Adrian Jr., R.J. Fox, J.E. Chick, A.D. Hunter, and R.A. Nicklow, "Chlorotitanium Enolate Addition to Aldimines: A Stereoselective Route to α-Oxy-β-Substituted β-Amino Esters," 65(19) The Journal of Organic Chemistry 6264-7, 2000
- Co-author with J.C. Adrian Jr. and L. Hassib, "β-Amino Acids via the Addition of Reformatsky Reagents to Imines: Restraining Effects of the o-Methoxyphenyl Substituent," 40 Tetrahedron Letters 2457, 1999
Select Publications
- Co-author with W.C. Trenkle, D.A. Sweigart, and S. Son, "Highly Efficient 1,4-Additions of Electron Deficient Aryl Boronic acids with a Novel Rh (I) Catalyst," 25(15) Organometallics 3548-51, 2006
- Co-author with M.D. Faust Jr. and W.C. Trenkle, "Cytosine Analogues from Substituted Acetonitriles via Thorpe Condensation," 5(18) Organic Letters 3333-5, 2003
- Co-author with J.C. Adrian Jr., R.J. Fox, J.E. Chick, A.D. Hunter, and R.A. Nicklow, "Chlorotitanium Enolate Addition to Aldimines: A Stereoselective Route to α-Oxy-β-Substituted β-Amino Esters," 65(19) The Journal of Organic Chemistry 6264-7, 2000
- Co-author with J.C. Adrian Jr. and L. Hassib, "β-Amino Acids via the Addition of Reformatsky Reagents to Imines: Restraining Effects of the o-Methoxyphenyl Substituent," 40 Tetrahedron Letters 2457, 1999
In addition to the Series A financing, Aeovian also announced that it has dosed the first cohort of participants in a Phase 1 clinical trial for its lead development candidate AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor. Supporting this transition into the clinic, the company has also expanded its leadership team with the appointment of seasoned industry veterans William Greene, M.D., Chief Investment Officer at Hevolution, and Justin Gover, former Chief Executive Officer of GW Pharmaceuticals, to the company's Board of Directors, and appointed Micah Zajic as Chief Financial Officer.
Genmab will acquire ProfoundBio for $1.8 billion in cash, payable at closing. The proposed transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to close in the first half of 2024, and is subject to the satisfaction of customary closing conditions.
The Wilson Sonsini team that advised ProfoundBio on patent matters related to the transaction includes Julia Minitti, Feng Tian, Hee Min Noh, and Jose Martinez.
For more information, please see ProfoundBio’s press release.
- Privacy Policy
- Terms of Use
- Accessibility